| Log in

Pharma M&A is an absolute seller’s market: Alpesh Dalal of Lupin

17 November, 2015

Lupin Ltd, India’s second largest drugmaker by market value, had been pursuing inorganic expansion during 2007-11, but had gone quiet on the mergers and acquisitions (M&A ....

To read the Full Story

Definitive news, exclusives, analyses and videos

  • Exclusive reporting, expert analysis and commentary on PE/VC/M&A deals & dealmakers
  • Daily, weekly and monthly curated newsletters on the deal ecosystem in India
  • Breaking news alerts
  • Participation in marquee events at concessional rates

Comprehensive | Accurate | Unbiased | Impeccably sourced


Leave Your Comment
Lupin to buy American generic drugmaker GAVIS for $880M in biggest overseas pharma M&A

Lupin to buy American generic drugmaker GAVIS for $880M in biggest overseas pharma M&A

Anuradha Verma 2 years ago
Lupin Ltd, India’s third-largest drugmaker by sales, has agreed to acquire...
Lupin to buy remaining 40% stake in South African generic drugmaker Pharma Dynamics

Lupin to buy remaining 40% stake in South African generic drugmaker Pharma Dynamics

Jasleen Kaur Batra 3 years ago
Mumbai-based pharma major Lupin Ltd has entered into an agreement to acquire the...
Lupin CFO Ramesh Swaminathan on growth strategy and new geographies it plans to enter

Lupin CFO Ramesh Swaminathan on growth strategy and new geographies it plans to enter

VCC Staff 3 years ago
Lupin is the second-largest pharma company in the country by market...
No Comments

Pharma M&A is an absolute seller’s market: Alpesh Dalal of Lupin

Powered by WordPress.com VIP